Electromedical Technologies Discusses FDA Approved Product, Benefits of Alternative Therapies and 2021 Outlook Among Topics Discussed by Company Founder and CEO Matthew Wolfson

Electromedical (OTC QB:EMED)


In this podcast, Mr. Wolfson discusses the current state
of Electromedical Technologies, their FDA approved product,
alternative therapies and 2021 outlook. Headquartered in
Scottsdale Arizona, Electromedical Technologies, Inc. (OTCQB:
EMED) is a commercial stage, FDA cleared, bioelectronic medical
device manufacturing company initially focused on the treatment
of various chronic, acute, intractable, and post-operative pain
conditions. Through university collaboration agreements the
company is working to develop a comprehensive research program in
defining the effects of electro-modulation on the human body by
studying the impacts of electrical fields in cell signaling and
effects on virus assembly and immune responses with the goal of
improving human wellbeing. The company’s current cleared product
indications are for chronic acute post traumatic and
post-operative, intractable pain relief.. For more information,
please visit the Company's website at
https://electromedtech.com/